Driving Regulatory Innovation: Automated Swap Data Reporting and Exception Management
DOI:
https://doi.org/10.15662/kmx41k35Keywords:
European Market Infrastructure Regulation (EMIR), Dodd-Frank Act, Regulatory Reporting Process, Exception Management, Regulatory ReportingAbstract
In this article, I discuss the ways in which technology has been used to build, implement, and maintain an automated report for the purpose of reporting swap transactions that are covered by the European Market Infrastructure Regulation (EMIR) and Dodd-Frank Act (DFA) Rule 12b-2. The automated report will use advances in technology, including but not limited to Artificial Intelligence (AI), Machine Learning (ML), and Natural Language Processing (NLP), to enhance the regulatory reporting process, exception management, and compliance with EMIR, DFA and across all regions of the globe. All automated reports will be designed so that companies can minimize their need to perform manual processing and maximize the quality, accuracy, and transparency of their reports by converting them to a single format and standardizing the way they collect and submit data to regulators. By utilizing the advanced analytics capabilities in combination with a real-time monitoring, companies will benefit from more timely swap reporting and will ultimately enhance the efficiency of markets for all types of securities. The automated reporting of swaps improves the environment for regulatory reporting in regard to the marketplace, provides a new baseline for the financial services industry's compliance with regulation, eliminates or reduces the possibility of violating regulatory requirements within the financial services sector, decreases the cost of regulatory penalties associated with non-compliance, and improves the reputation of the organization overall.
References
1. “The CFTC's Swap Data Overhaul”, Heath Tarbert, Daniel Grimm, July 20, 2021, https://papers.ssrn.com/sol3/papers.cfm?abstract_id
=3890501.
2. “CFTC NEW RULES FOR SWAP DATA REPORTING”, Salim Modi, Matthew Rodgers, Spencer Schulten, 30 November 2020,
https://www.capco.com/intelligence/capco- intelligence/cftc-new-rules-for-swap-data- reporting.
3. “Swap Data Recordkeeping and Reporting Requirements”, 11/25/2020, https://www.federalregister.gov/documents/2020/1 1/25/2020-21569/swap-data-recordkeeping-and- reporting-requirements.
4. “Automation Trends Report 2022: The Speed of Change”, 2022, https://acarp-edu.org/automation- trends-report-2022-the-speed-of-change/.
5. “Swap Data Recordkeeping and Reporting Requirements: Pre-Enactment and Transition Swaps”, 2012,
https://www.cftc.gov/sites/default/files/idc/groups/ public/@newsroom/documents/file/ federalregister051812.pdf.
6. “CFTC Overhauls Swaps Reporting Rules”, A L E R T M E M OR A N D UM, October 7, 2020,https://www.clearygottlieb.com/-
/media/files/alert-memos-2020/2020_10_07-cftc- overhauls-swaps-reporting-rules-pdf.pdf.
7. “ISDA/SIFMA Comments on CFTC DMO Roadmap for Swap Data Reporting”, 2017, https://www.isda.org/a/wZiDE/isda-sifma- comments-cftc-dmo-roadmap-swap-data-reporting- 21-aug-2017-final.pdf.
8. “Report on OTC derivatives data reporting and aggregation requirements”, January 2012, https://www.bis.org/cpmi/publ/d100.pdf.
9. “10-Ks information extraction case studies”, July 06, 2022, https://snorkel.ai/blog/10-ks-information- extraction-case-studies/.
10. “Swap Data Repository and Data Standards”, February 25, 2014, https://www.financialresearch.gov/frac/2014/02/25/ committee-meeting/discussion-topic/swap-data- repository-and-data-standards/.
11. “A Global Swap Data Repository Service”, January, 2012, https://www.ice.com/publicdocs/technology/ICE_T rade_Vault_White_Paper.pdf.
12. “Impact of source data verification on data quality in clinical trials: an empirical post hoc analysis of three phase 3 randomized clinical trials”, Jeppe Ragnar Andersen, Inger Byrjalsen, Asger Bihlet, Faidra Kalakou, Hans Christian Hoeck, Gitte Hansen, Henrik Bo Hansen, Morten Asser Karsdal, Bente Juel Riis, 2014 Oct 19, https://doi.org/10.1111/bcp.12531.
13. “Central statistical monitoring in multicentre clinical trials: developing statistical approaches for analysing key risk indicators”, Elsa Valdes- Marquez, Jemma C Hopewell, Jane Armitage, Martin Landray, 2013 Nov 29, https://doi.org/10.1186/1745-6215-14-S1-P139





